Genmab Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GA</div>
GMAB -- Denmark Stock  

DKK 2,028  53.00  2.68%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Genmab AS is 'Hold'. Macroaxis provides Genmab AS buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GMAB positions. The advice algorithm takes into account all of Genmab AS available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GMAB buy-and-hold perspective. Please check Genmab AS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Search Advice


Time Horizon

Risk Tolerance

Execute Advice
Sell Genmab ASBuy Genmab AS


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Genmab AS has a risk adjusted performance of 0.458, jensen alpha of 0.4024, total risk alpha of 0.4764, sortino ratio of 0.1156 and treynor ratio of 1.35
Macroaxis provides buy, hold, or sell recommendation on Genmab AS to complement and cross-verify current analyst consensus">analyst consensus on Genmab AS. Our buy or sell recommendations engine determines the entity potential to grow exclusively from the perspective of investors current risk tolerance and investing horizon. To make sure Genmab AS is not overpriced, please check out all Genmab AS fundamentals, including its Price to Sales, Gross Profit and the relationship between Price to Book and Revenue .

Genmab AS Trading Alerts and Improvement Suggestions

Genmab AS has very high historical volatility over the last 30 days

Genmab AS Returns Distribution Density

Mean Return0.38Value At Risk-5.81
Potential Upside5.50Standard Deviation3.38
 Return Density 

Genmab AS Greeks

Alpha over DOW
Beta against DOW=0.27
Overall volatility
Information ratio =0.15

Genmab AS Volatility Alert

Genmab AS shows above average downside volatility of 4.34 for selected time horizon. We advise investors to further inspect Genmab AS to make sure all market timing and asset allocation strategies are consistent with estimation about Genmab AS future alpha.
 Better Than Average     
 Worse Than Average Compare Genmab AS to competition

Genmab AS Fundamental Vs Peers

FundamentalsGenmab ASPeer Average
Return On Equity19.64 (0.31) 
Return On Asset13.97 (0.14) 
Profit Margin40.37 (1.27) 
Operating Margin49.16 (5.51) 
Current Valuation92.35 B16.62 B
Shares Outstanding65.05 M571.82 M
Price to Earning47.06 28.72 
Price to Book7.42 9.51 
Price to Sales19.41 11.42 
Revenue5.37 B9.43 B
Gross Profit5.37 B27.38 B
EBITDA2.78 B3.9 B
Net Income2.17 B570.98 M
Cash and Equivalents10.97 B2.7 B
Cash per Share168.59 5.01 
Total Debt181 M5.32 B
Debt to Equity0.012 48.70 
Current Ratio14.88 2.16 
Book Value Per Share215.88 1.93 K
Cash Flow from Operations1.33 B971.22 M
Earnings Per Share34.03 3.12 
Number of Employees54818.84 K
Market Capitalization104.17 B19.03 B

About Genmab AS Buy or Sell Advice

When is the right time to buy or sell Genmab AS? Buying stocks such as Genmab AS isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily bases. Although Genmab AS investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply. Please read more on our stock advisor page.

Did You Try This Idea?

Run Drugs Thematic Idea Now

Drugs Theme
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Drugs theme has 30 constituents.
View All  Next Launch Drugs
Please check Genmab AS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page